Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Authors
Chen, LSiveke, J
Wang-Gillam, A
Hubner, Richard A
Pant, S
Dragovich, T
Chung, V
Chang, D
Ross, P
Cooray, P
Tebbutt, N
Franke, F
Belanger, B
Dhindsa, N
de Jong, F
Mamlouk, K
Von Hoff, D
Affiliation
National Health Research Institutes (NHRI) – National Institute of Cancer Research, Tainan, TaiwanIssue Date
2016